Skip to Content
Merck
CN

1539905

USP

Pioglitazone hydrochloride

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione monohydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C19H20N2O3S · HCl
CAS Number:
112529-15-4
Molecular Weight:
392.90
NACRES:
NA.24
PubChem Substance ID:
329750847
UNSPSC Code:
41116107
MDL number:
MFCD04975446

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Pioglitazone hydrochloride, United States Pharmacopeia (USP) Reference Standard

InChI

1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H

SMILES string

Cl.CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1

InChI key

GHUUBYQTCDQWRA-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

pioglitazone

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... PPARG(5468)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Pioglitazone hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Pioglitazone and Metformin Hydrochloride Tablets
  • Pioglitazone Tablets
  • Pioglitazone and Glimepiride Tablets

Biochem/physiol Actions

Pioglitazone hydrochloride is a PPARγ agonist and thiazolidinedione (TZD) anti-diabetic.
Pioglitazone hydrochloride is a PPARγ agonist and thiazolidinedione (TZD) anti-diabetic. Pioglitazone is a selective agonist of the nuclear receptor peroxisome proliferator-activated receptor γ (PPAR-γ) and to a lesser extent PPAR-α.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

hcodes

H302,H351

Hazard Classifications

Acute Tox. 4 Oral - Carc. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The use of oral pioglitazone in the treatment of lichen planopilaris.
Natasha Atanaskova Mesinkovska et al.
Journal of the American Academy of Dermatology, 72(2), 355-356 (2015-01-17)
Chin-Hsiao Tseng
Metabolism: clinical and experimental, 63(8), 1049-1055 (2014-06-04)
To investigate whether pioglitazone treatment of patients with type 2 diabetes mellitus was associated with an increased risk of kidney cancer. The reimbursement databases of all Taiwanese patients with type 2 diabetes who received oral anti-diabetic agents or insulin from
W Xu et al.
Journal of internal medicine, 277(1), 137-150 (2014-07-22)
Progressive β-cell dysfunction hinders the maintenance of glycaemic control in type 2 diabetes, but comparative data on β-cell-protective therapies are lacking in the early stage of type 2 diabetes. Here we evaluated the comparative glycaemic efficacy and impact on β-cell
Anti-hyperglycemic activity of rutin in streptozotocin-induced diabetic rats: an effect mediated through cytokines, antioxidants and lipid biomarkers.
Niture NT, Ansari AA, and Naik SR
Indian Journal of Experimental Biology, 52(7), 720-727 (2014)
Catherine M Viscoli et al.
American heart journal, 168(6), 823-829 (2014-12-03)
Recurrent vascular events remain a major source of morbidity and mortality after stroke or transient ischemic attack (TIA). The IRIS Trial is evaluating an approach to secondary prevention based on the established association between insulin resistance and increased risk for
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service